rare cancers
play

Rare cancers What is the problem, and how big is it? Rare (orphan) - PowerPoint PPT Presentation

Jan 09, 2023 •328 likes •779 views

Rare cancers What is the problem, and how big is it? Rare (orphan) diseases NIH Office for Rare Diseases Prevalence less than 5/10 000 in the community In the US <200 000 cases Eurodis (European Organisation for Rare Diseases)

  1. Rare cancers

  2. What is the problem, and how big is it?

  3. Rare (orphan) diseases NIH Office for Rare Diseases • Prevalence less than 5/10 000 in the community • In the US <200 000 cases Eurodis (European Organisation for Rare Diseases) • 5-8 000 distinct conditions • Affect 6-8% of the population Cancer • EUROCARE working group definition of ‘ very rare ’ diseases Annual crude incidence rates <2/100 000 for both sexes combined (Gatta et al 2006 Lancet Oncology 7:132) • Rare = <6/100,000 • Less common = 6-12/100,000 • >186 cancer types

  4. Collective Impact of Rare Cancers on the Community New cases Deaths Per cent Per cent Cancer site/type (ICD-10 codes) Number of total Rate(b) Risk(c) Number of total Rate(b) PYLL(d) Males Prostate (C61) 15,759 28.7 163.4 1 in 5 2,792 12.9 33.0 20,560 Colorectal (C18 – C20) 7,160 13.0 75.1 1 in 10 2,196 10.1 23.8 30,770 Lung, bronchus & trachea (C33 – C34) 5,826 10.6 61.6 1 in 11 4,733 21.8 50.8 64,090 Melanoma of skin (C43) 5,503 10.0 56.6 1 in 15 815 3.8 8.7 14,868 Lymphoma (C81 – C85, C96) 2,352 4.3 24.3 1 in 33 803 3.7 8.8 12,260 Unknown primary site (C26, C39, C76 – C80) 1,700 3.1 18.5 1 in 40 1,781 8.2 19.7 23,385 Bladder (C67) 1,642 3.0 17.9 1 in 39 589 2.7 6.8 5,308 Leukaemia (C91 – C95) 1,578 2.9 16.8 1 in 47 833 3.8 9.3 12,148 Kidney (C64) 1,395 2.5 14.2 1 in 55 497 2.3 5.3 7,670 Stomach (C16) 1,275 2.3 13.6 1 in 52 720 3.3 7.9 9,818 Other 10,680 19 111 NA 5,911 27 64 94,205 All cancers (C00 – C97(a), D45 – D47(e)) 54,870 100.0 573.4 1 in 2 21,670 100.0 237.5 295,080 Females Breast (C50) 12,126 27.9 112.8 1 in 9 2,664 15.8 23.8 48,910 Colorectal (C18 – C20) 5,817 13.4 51.5 1 in 14 1,872 11.1 16.0 21,798 Melanoma of skin (C43) 4,219 9.7 39.4 1 in 24 385 2.3 3.4 6,790 Lung, bronchus & trachea (C33 – C34) 3,270 7.5 29.3 1 in 24 2,526 15.0 22.3 34,770 Lymphoma (C81 – C85, C96) 1,920 4.4 17.5 1 in 46 736 4.4 6.3 8,725 Uterus, body (C54) 1,718 4.0 15.8 1 in 52 202 1.2 1.8 2,510 Unknown primary site (C26, C39, C76 – C80) 1,592 3.7 13.6 1 in 54 1,741 10.4 14.5 17,635 Ovary (C56) 1,246 2.9 11.4 1 in 73 851 5.1 7.6 13,083 Thyroid (C73) 1,128 2.6 10.9 1 in 103 51 0.3 0.4 555 Leukaemia (C91 – C95) 1,087 2.5 9.8 1 in 83 612 3.6 5.2 8,350 Other 9,343 21 83 NA 5,179 31 44 66,358 All cancers (C00 – C97(a), D45 – D47(e)) 43,466 100.0 395.4 1 in 3 16,819 100.0 145.8 229,483 20,023: 20.4% 11,090: 28.8% 160,563: 30.6% Australian Institute of Health and Welfare

  5. Collective Impact of Rare Cancers on the Community New cases Deaths Per cent of Per cent of Cancer site/type (ICD-10 codes) Number total Rate(b) Risk(c) Number total Rate(b) PYLL(d) Males Prostate (C61) 15,759 28.7 163.4 1 in 5 2,792 12.9 33.0 20,560 Colorectal (C18 – C20) 7,160 13.0 75.1 1 in 10 2,196 10.1 23.8 30,770 Lung, bronchus & trachea (C33 – C34) 5,826 10.6 61.6 1 in 11 4,733 21.8 50.8 64,090 Melanoma of skin (C43) 5,503 10.0 56.6 1 in 15 815 3.8 8.7 14,868 Lymphoma (C81 – C85, C96) 2,352 4.3 24.3 1 in 33 803 3.7 8.8 12,260 Unknown primary site (C26, C39, C76 – C80) 1,700 3.1 18.5 1 in 40 1,781 8.2 19.7 23,385 1:100,000 = 2,224 Australian deaths each year Bladder (C67) 1,642 3.0 17.9 1 in 39 589 2.7 6.8 5,308 Leukaemia (C91 – C95) 1,578 2.9 16.8 1 in 47 833 3.8 9.3 12,148 Kidney (C64) 1,395 2.5 14.2 1 in 55 497 2.3 5.3 7,670 Stomach (C16) 1,275 2.3 13.6 1 in 52 720 3.3 7.9 9,818 Other 10,680 19 111 NA 5,911 27 64 94,205 All cancers (C00 – C97(a), D45 – D47(e)) 54,870 100.0 573.4 1 in 2 21,670 100.0 237.5 295,080 6/100,000 = 14,000 deaths Females Breast (C50) 12,126 27.9 112.8 1 in 9 2,664 15.8 23.8 48,910 Colorectal (C18 – C20) 5,817 13.4 51.5 1 in 14 1,872 11.1 16.0 21,798 Melanoma of skin (C43) 4,219 9.7 39.4 1 in 24 385 2.3 3.4 6,790 Lung, bronchus & trachea (C33 – C34) 3,270 7.5 29.3 1 in 24 2,526 15.0 22.3 34,770 Lymphoma (C81 – C85, C96) 1,920 4.4 17.5 1 in 46 736 4.4 6.3 8,725 Uterus, body (C54) 1,718 4.0 15.8 1 in 52 202 1.2 1.8 2,510 Unknown primary site (C26, C39, C76 – C80) 1,592 3.7 13.6 1 in 54 1,741 10.4 14.5 17,635 Ovary (C56) 1,246 2.9 11.4 1 in 73 851 5.1 7.6 13,083 Thyroid (C73) 1,128 2.6 10.9 1 in 103 51 0.3 0.4 555 Leukaemia (C91 – C95) 1,087 2.5 9.8 1 in 83 612 3.6 5.2 8,350 Other 9,343 21 83 NA 5,179 31 44 66,358 All cancers (C00 – C97(a), D45 – D47(e)) 43,466 100.0 395.4 1 in 3 16,819 100.0 145.8 229,483 Australian Institute of Health and Welfare

Recommend

Outline enhanced diagnostics and potential treatment strategies To understand rare cancers

Outline enhanced diagnostics and potential treatment strategies To understand rare cancers

5/25/2018 Pathognomonic mutations in rare gynecologic cancers: from discovery to Outline enhanced diagnostics and potential treatment strategies To understand rare cancers as histo- molecular entities Pathognomonic mutations: where

592 views • 18 slides
Uncontrolled evidence in rare cancers Paolo G. Casali paolo.casali@istitutotumori.mi.it R Eur

Uncontrolled evidence in rare cancers Paolo G. Casali paolo.casali@istitutotumori.mi.it R Eur

Uncontrolled evidence in rare cancers Paolo G. Casali paolo.casali@istitutotumori.mi.it R Eur Eur J C J Can ance cer 201 r 2011;47 1;47:249 :2493 Clinical decision-making Methods to combine evidence New study designs

788 views • 64 slides
EUROPEAN REFERENCE NETWORKS Matt Bolz-Johnson, EURORDIS Rare Disease Ireland, Dublin, Ireland

EUROPEAN REFERENCE NETWORKS Matt Bolz-Johnson, EURORDIS Rare Disease Ireland, Dublin, Ireland

EUROPEAN REFERENCE NETWORKS Matt Bolz-Johnson, EURORDIS Rare Disease Ireland, Dublin, Ireland 23 October 2018 Challenges we face as a community Rare diseases and rare cancers can be chronic, progressive, degenerative, disabling and

711 views • 25 slides
Interval cancers Intrinsic subtypes Interval cancers arise symptomatically between screening

Interval cancers Intrinsic subtypes Interval cancers arise symptomatically between screening

6/9/2017 Using a polygenic risk score and breast density to predict interval cancers Disclosures Yiwey Shieh, MD UCSF Division of General Internal Medicine I have no potential conflicts of interest to disclose. I am a general internist.

704 views • 12 slides
Skin Cancers and Common Spots Common lesions Skin cancers Non melanoma Lindy P.

Skin Cancers and Common Spots Common lesions Skin cancers Non melanoma Lindy P.

Outline Skin Cancers and Common Spots Common lesions Skin cancers Non melanoma Lindy P. Fox, MD Melanoma Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San

465 views • 18 slides
RAREDISEASEDAY.ORG 1 Rare Disease Day 2020 13 th edition on Saturday 29 February 2020

RAREDISEASEDAY.ORG 1 Rare Disease Day 2020 13 th edition on Saturday 29 February 2020

RAREDISEASEDAY.ORG 1 Rare Disease Day 2020 13 th edition on Saturday 29 February 2020 A rare day for rare diseases in this leap year! Key campaign message: Rare is many. Rare is strong. Rare is proud! RAREDISEASEDAY.ORG 2

853 views • 15 slides
ISBT WORKING PARTY ON RARE DONORS Israel Have a national Rare Donor Program: Yes Number of

ISBT WORKING PARTY ON RARE DONORS Israel Have a national Rare Donor Program: Yes Number of

ISBT WORKING PARTY ON RARE DONORS Israel Have a national Rare Donor Program: Yes Number of Donors in Database: Rare 1000,Ag- ~ 20,000 Definition of Rare: &lt;1: 1000, or rare combination Number of Frozen Rare Cells: 1500 How are Rare Donors

428 views • 3 slides
Urological cancers why we need to change Clinical workshop 12 March 2013 Introduction

Urological cancers why we need to change Clinical workshop 12 March 2013 Introduction

Urological cancers why we need to change Clinical workshop 12 March 2013 Introduction and welcome Todays event aims to cover: 1. London Cancers recommendations for Professor Kathy Pritchard-Jones change Chief Medical Officer,

368 views • 23 slides
Mission To support those affected by blood cancers such as leukemia, lymphoma, and myeloma while

Mission To support those affected by blood cancers such as leukemia, lymphoma, and myeloma while

Mission To support those affected by blood cancers such as leukemia, lymphoma, and myeloma while they are receiving care in Rochester, MN in order to promote healing and peace of mind. Vision To ensure every patient battling blood cancers while

536 views • 12 slides
ISBT WORKING PARTY ON RARE DONORS Canada Canadian Blood Services Have a national Rare Donor

ISBT WORKING PARTY ON RARE DONORS Canada Canadian Blood Services Have a national Rare Donor

ISBT WORKING PARTY ON RARE DONORS Canada Canadian Blood Services Have a national Rare Donor Program: Yes Number of Donors in Database: Rare donor code 6260: 1849 donors coded Definition of Rare: A donation/RBC is considered to be rare

67 views • 6 slides
demand for.. Rare Metals Research Capital Rare Metals Conference, April 30, 2008

demand for.. Rare Metals Research Capital Rare Metals Conference, April 30, 2008

AVL:TSX the way to play the surging demand for.. Rare Metals Research Capital Rare Metals Conference, April 30, 2008 www.avalonventures.com 1 Rare Metals Project Locations Thor Lake Rare Earths Tantalum-Cesium Tantalum Lithium

3.06k views • 29 slides
Prevalence of Occupational Cancers Incidence &gt;5000 new cases per year 11%

Prevalence of Occupational Cancers Incidence &gt;5000 new cases per year 11%

Peering through the Retrospectoscope: Taking an Occupational History Dr Euan Thompson Occupational Physician Prevalence of Occupational Cancers Incidence &gt;5000 new cases per year 11% of cancers (men) / 2% (women)

672 views • 16 slides
ISBT WORKING PARTY ON RARE DONORS SINGAPORE Have a national Rare Donor Program: YES Number of

ISBT WORKING PARTY ON RARE DONORS SINGAPORE Have a national Rare Donor Program: YES Number of

ISBT WORKING PARTY ON RARE DONORS SINGAPORE Have a national Rare Donor Program: YES Number of Donors in Database: 8 donors Definition of Rare: 1:1000 Number of Frozen Rare Cells: 16 units How are Rare Donors found?: Screened &amp; ABID Number

326 views • 3 slides
3/7/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/7/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/7/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th Multidisciplinary Management of Cancers: A Casebased Approach Panel Members Lymphoma Tumor Board Ranjana Advani, MDSaul A. Rosenberg, Professor of

317 views • 15 slides
3/13/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/13/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/13/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th Multidisciplinary Management of Cancers: A Casebased Approach Panel Members Jason Gotlib, MD, MS Professor of Medicine, Hematology; Stanford

519 views • 24 slides
Rare Metals September 20, 2007 AVALONS RARE METALS FOCUS: Leveraged to advances in

Rare Metals September 20, 2007 AVALONS RARE METALS FOCUS: Leveraged to advances in

The Next Big Thing: Rare Metals September 20, 2007 AVALONS RARE METALS FOCUS: Leveraged to advances in high-technology and clean energy generation Materials science is increasingly exploiting the unique properties of rare metals

317 views • 28 slides
3/7/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/7/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/7/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th Multidisciplinary Management of Cancers: A Casebased Approach Breast Tumor Board 2018 Assistant to Chair: Joshua Gruber, MD, PhD Instructor in Medicine

434 views • 19 slides
and daily life: The Balancing Act of the Rare Disease Community Avril Daly, EURORDIS

and daily life: The Balancing Act of the Rare Disease Community Avril Daly, EURORDIS

Juggling care and daily life: The Balancing Act of the Rare Disease Community Avril Daly, EURORDIS Vice-President 17 th October 2017 Launch event of the Parliamentary Advocates for Rare Diseases #ParliamentAdvocate4Rare Rare diseases A rare

833 views • 26 slides
CME / CE Rare Disease Clinical Trials Module: Rare Pulmonology Clinical Trials Timothy Craig,

CME / CE Rare Disease Clinical Trials Module: Rare Pulmonology Clinical Trials Timothy Craig,

CME / CE Rare Disease Clinical Trials Module: Rare Pulmonology Clinical Trials Timothy Craig, DO Penn State Health Rare Hematologic Conditions Rare Pulmonology Conditions What is a rare disease? A rare disease is any disease affecting

405 views • 14 slides
3/7/2017 17 th Multidisciplinary Management of Cancers: A Case based Approach 17 th

3/7/2017 17 th Multidisciplinary Management of Cancers: A Case based Approach 17 th

3/7/2017 17 th Multidisciplinary Management of Cancers: A Case based Approach 17 th Multidisciplinary Management of Cancers: A Case based Approach Panel Members Lauren Maeda, MD Clinical Assistant Professor, Hematology/Oncology,

500 views • 15 slides
3/7/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/7/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/7/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th Multidisciplinary Management of Cancers: A Casebased Approach Case 1: A 45 year old woman with metastatic lung adenocarcinoma and polyarthralgias 2018

377 views • 20 slides
Gene Therapies for Rare Diseases September 13, 2018 Rare Disease Scientific Workshop Everylife

Gene Therapies for Rare Diseases September 13, 2018 Rare Disease Scientific Workshop Everylife

Gene Therapies for Rare Diseases September 13, 2018 Rare Disease Scientific Workshop Everylife Foundation for Rare Diseases Washington, DC Wilson W. Bryan Office of Tissues and Advanced Therapies (OTAT) Center for Biologics Evaluation and

510 views • 20 slides
ISBT WORKING PARTY ON RARE DONORS INDIA Have a national Rare Donor Program: No. Number of Donors

ISBT WORKING PARTY ON RARE DONORS INDIA Have a national Rare Donor Program: No. Number of Donors

ISBT WORKING PARTY ON RARE DONORS INDIA Have a national Rare Donor Program: No. Number of Donors in Database: ----- Definition of Rare: Lacking high incidence antigens or lacking a combination of common antigens Number of Frozen Rare Cells:

156 views • 3 slides
3/13/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/13/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th

3/13/2018 18 th Multidisciplinary Management of Cancers: A Casebased Approach 18 th Multidisciplinary Management of Cancers: A Casebased Approach Matthew Gubens, MD MS, UC San Francisco, Chair Julia Rotow, MD, UC San Francisco, Fellow

302 views • 15 slides

More recommend